Aeira brings proven, ICH-compliant innovative medicines to patients across emerging markets — genuine innovation they can actually afford.
"Continuity in healing, connection in science, and care without borders."
Across emerging markets, patients wait years for medicines already proven elsewhere — and even then, they remain out of reach for most.
Aeira closes that gap. We in-license innovative therapies already approved in an established market — chosen for a meaningful cost advantage, never at the expense of quality or safety — and bring them to market locally, carrying only approval risk, never development risk.
The result is access: the same molecule, the same standard of evidence, delivered closer, sooner, and within reach.
We license molecules that are already approved and manufactured to ICH/GMP standards, then win local approval and reach patients. Our edge is the pathway — not the lab.
Me-too / me-better innovative drugs already approved in an established market and ICH-compliant — selected for meaningful cost differentiation, never at the expense of quality or safety.
A regulatory-led team — including ex-MNC leadership — secures registration across emerging-market regulatory authorities.
With corporate hubs in Singapore and Hong Kong, we build commercial reach market by market — expanding across emerging markets as the portfolio matures.
Bringing a proven medicine to a new market hinges on one thing — winning local approval. It's where most cross-border plays stall, and where Aeira is built to excel.
End-to-end Common Technical Document preparation, mapped to each authority's exact requirements.
From source-market approval to ASEAN and Central Asian filings, we chart the fastest compliant route to registration.
Regulator questions answered within mandated response windows — keeping approval timelines on track.
A regulatory function led by an ex-MNC Head of Regulatory Affairs, with deep cross-border, emerging-market experience.
Our structure is deliberately aligned — what serves our partners serves our investors, and the mission is one worth building a career around.
Bring us your approved molecule — we carry local registration and commercialization. You reach emerging markets without standing up regional infrastructure or taking on in-market risk.
We license proven, already-approved therapies rather than funding discovery. Capital compounds across a growing platform of registrations in one of the world's fastest-growing healthcare regions.
A senior, regulatory-led team — including ex-MNC leadership — building medicine access at regional scale. High ownership, real impact, and none of the bureaucracy.
| Therapeutic Area | Stage |
|---|---|
| Immunology | Dossier compilation · est. submission Q4 2026 |
| Oncology | In-licensing · term-sheet stage |
| Metabolic & Cardiovascular | Sourcing · candidate review |
These first markets are only the beginning. Aeira's ambition is to become the world's leading commercial gateway for proven, affordable medicines — carrying quality assets to every emerging market on earth, from Central Asia to the Middle East, Europe, and Africa.
For partners, originators, and investors who want to reach the next billion patients.
Prefer email? stan.wu@aeira.com